Edge-To-Edge Valve Repair

In patients with HF and secondary mitral regurgitation, transcatheter edge-to-edge repair was noninferior to mitral valve surgery for efficacy and was linked with fewer safety endpoint events, according to data from the MATTERHORN trial.

Transcatheter mitral valve repair in addition to medical therapy led to a lower rate of CV events and hospitalizations and better health status compared with medical therapy alone for patients with HF and moderate to severe mitral regurgitation.

Abbott announced the FDA approved its novel transcatheter edge-to-edge repair system designed for the treatment of tricuspid regurgitation.

An FDA advisory panel voted 13-1 that the benefits of a transcatheter edge-to-edge repair device outweigh any risks in adults with symptomatic severe tricuspid regurgitation, despite no improvement in hard endpoints seen in a pivotal trial.

In patients with HF and severe secondary mitral regurgitation, transcatheter edge-to-edge mitral valve repair reduced mortality and HF hospitalization regardless of whether patients had malnutrition, new data from the COAPT trial show.

In older patients with severe or worse tricuspid regurgitation, a tricuspid transcatheter edge-to-edge repair system was safe and improved tricuspid regurgitation grade and quality of life measures for the sickest patients, data show.

NEW ORLEANS — An analysis of the STS/ACC TVT registry showed that successful transcatheter edge-to-edge repair for degenerative mitral regurgitation was safe and significantly improved symptoms and mortality at 1 year, a speaker reported.

Access to transcatheter edge-to-edge repair for degenerative mitral regurgitation did not impact annualized surgical mitral valve repair volume, though data suggest access led to improvements in surgery outcomes and 5-year mortality rates.